Poseida Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Collaboration revenue
Collaboration Revenue
Total collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest expense
Other income, net
Net loss before income tax
Income tax expense
Net loss
Other comprehensive income (expense):
Other comprehensive income (loss) (net of tax expense of $0 for each of the periods ending December 31, 2020 and 2019)
Total other comprehensive income (loss)
Unrealized gain (loss) on short-term investments
Comprehensive loss
Net loss per share attributable to common stockholders, basic and diluted
Weighted-average number of shares outstanding, basic and diluted
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted
Weighted-average number of shares outstanding, basic
Weighted-average number of shares outstanding, diluted

Comments